Can you take Procarbazine with Quadramet?
1 drug interaction and 7 additional warnings found for the following 2 drugs:
- procarbazine
- Quadramet (samarium sm 153 lexidronam)
Drug interactions
Major drug interactions
Major:
procarbazine samarium sm 153 lexidronam
Applies to: procarbazine and Quadramet (samarium sm 153 lexidronam)
Using samarium sm 153 lexidronam together with procarbazine may increase the risk of side effects that affect your bone marrow function, resulting in low numbers of different types of blood cells. You may be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. You should seek medical attention if you develop paleness, fatigue, dizziness, fainting, unusual bruising or bleeding, fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Major food/lifestyle interactions
Major:
procarbazine Food/Lifestyle
Applies to: procarbazine
During and within two weeks after treatment with procarbazine, you must not consume any foods or beverages that are high in tyramine content. Doing so can raise your blood pressure to dangerous levels, a condition known as hypertensive crisis. The condition is potentially fatal and may cause symptoms such as severe headache, confusion, blurred vision, problems with speech or balance, nausea, vomiting, chest pain, convulsions, and sudden numbness or weakness (especially on one side of the body). You should seek immediate medical attention if you have any of these symptoms. Foods that are high in tyramine include, but are not limited to, air dried meats; aged or fermented meats; sausage or salami; pickled herring; anchovies; liver; red wine; beer; aged cheeses, including blue, brick, brie, cheddar, parmesan, romano, and swiss; sour cream; sauerkraut; canned figs; raisins; bananas or avocados (particularly if overripe); soy beans; soy sauce; tofu; miso soup; bean curd; fava beans; or yeast extracts (such as Marmite). You should avoid the use of alcohol while being treated with procarbazine, as alcohol may increase some of the nervous system side effects such as dizziness, drowsiness, and difficulty concentrating. Also avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. Talk to your doctor or pharmacist if you have any questions or concerns.
Disease interactions
6 potential interactions Applies to: 6 conditions, including Fever, Liver Disease, Infection, Bleeding Disorder, and Renal Dysfunction.
Bleeding Disorder
Major:
procarbazine
Procarbazine has a major potential interaction with Bleeding Disorder.
Procarbazine induces myelosuppression, including thrombocytopenia. Bleeding tendencies have included petechiae, purpura, epistaxis, hemoptysis, hematuria, and melena. Therapy with procarbazine should be administered cautiously in patients with bleeding tendencies. Patients should be instructed to immediately report any signs or symptoms of bleeding. Procarbazine should be withheld and/or discontinued if bleeding occurs. Therapy should be withheld if white blood cell counts fall below 4000/mm3 and/or platelet counts fall below 100,000/mm3. Clinical monitoring of hematopoietic function is recommended.
Bone Marrow Depression/Low Blood Counts
Major:
procarbazine
Procarbazine has a major potential interaction with Bone Marrow Depression/Low Blood Counts.
Procarbazine induces myelosuppression. Leukopenia, thrombocytopenia, and anemia have been reported during procarbazine therapy. Therapy with procarbazine is contraindicated in patients with inadequate bone marrow reserve as demonstrated by bone marrow aspiration, and should be administered after cautious consideration in patients whose bone marrow reserve may be severely depressed by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Therapy should be withheld if leukocyte counts fall below 4000/mm3 and/or platelet counts fall below 100,000/mm3. Close monitoring of hematopoietic function is recommended.
Fever
Major:
procarbazine
Procarbazine has a major potential interaction with Fever.
Procarbazine induces myelosuppression. Leukopenia, thrombocytopenia, and anemia have been reported during procarbazine therapy. Therapy with procarbazine is contraindicated in patients with inadequate bone marrow reserve as demonstrated by bone marrow aspiration, and should be administered after cautious consideration in patients whose bone marrow reserve may be severely depressed by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Therapy should be withheld if leukocyte counts fall below 4000/mm3 and/or platelet counts fall below 100,000/mm3. Close monitoring of hematopoietic function is recommended.
Infection
Major:
procarbazine
Procarbazine has a major potential interaction with Infection.
Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.
Liver Disease
Moderate:
procarbazine
Procarbazine has a moderate potential interaction with Liver Disease.
Procarbazine is metabolized by liver and kidney. Patients with hepatic impairment may be at increased risk for toxicity from procarbazine therapy at recommended dosages. Therapy with procarbazine should be administered cautiously in patients with compromised hepatic function.
Renal Dysfunction
Moderate:
procarbazine
Procarbazine has a moderate potential interaction with Renal Dysfunction.
Procarbazine is metabolized by the liver and kidney. Approximately 70 % of procarbazine is excreted in the urine. Patients with renal impairment may be at increased risk for toxicity from procarbazine therapy at recommended dosages. Therapy with procarbazine should be administered cautiously in patients with compromised renal function.
Report options
More resources
procarbazine
A total of 570 drugs are known to interact with procarbazine.
- Procarbazine is in the drug class miscellaneous antineoplastics.
- Procarbazine is used to treat the following conditions:
Quadramet
A total of 223 drugs are known to interact with Quadramet.
- Quadramet is in the drug class therapeutic radiopharmaceuticals.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.